Intensity Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
29.4%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$3.85next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 26 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly10.2MTarget: Sufficient capital to fund operations beyond the second quarter of 2027
INVINCIBLE-3 Phase 3 Sarcoma Trial Enrollment Quarterly21.0Target: Resume enrollment in a limited number of U.S. sites by Q3 2026 and expand globally upon securing additional funding
INVINCIBLE-4 Phase 2 TNBC Trial Enrollment Quarterly14.0Target: Targeting completion of enrollment for the INVINCIBLE-4 Phase 2 breast cancer study by end of 2027, subject to funding availability
Watch Items
- Capital Runway and Going Concern StatusTrigger: Cash balance falling below $5.0 million without securing incremental non-dilutive or equity financingAction: Accelerate utilization of the $60 million ATM facility or seek strategic licensing partnerships to avoid operational halts.
- INVINCIBLE-3 Trial Site Re-activationsTrigger: Failure to resume patient enrollment in U.S. sites by September 30, 2026Action: Re-evaluate clinical trial timeline, CRO agreements, and prioritize capital allocation to the less capital-intensive INVINCIBLE-4 study.
- Regulatory Approvals for Protocol AmendmentsTrigger: Delays in obtaining Swissmedic or FDA approvals for modified dosing protocolsAction: Engage in direct regulatory consultations to address safety concerns regarding localized skin irritation.
Research as of 20 Jun 2026